Condition
Schizophrenia Clinical Trials
Studies of schizophrenia, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 556Psychotic Disorders, Family Members
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one.
- Conditions
- Psychotic Disorders, Family Members, Anosognosia, Paranoia
- Trial name
- NCT05500001
- Testing
- Supporting Patients by Family Education in Psychotic Illness Group
- Where
- 4 sites in Canada
- Volunteers
- 113 people
- Sponsor
- University of Alberta
First Episose Psychosis, Metabolic Disease
The ATP Project (Antipsychotic-TEP-Psychosis)
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.
- Conditions
- First Episose Psychosis, Metabolic Disease, Psychosis; Episode
- Trial name
- ATP (NCT06651112)
- Testing
- Antipsychotic drugs
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Université de Sherbrooke
Schizophrenia
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the…
- Trial name
- NCT04959201
- Testing
- NMDAE plus AO
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Patients With Schizophrenia-like Disorders
Interest of the Tool: Evaluation of Specific Care in an Ecological Environment for Patients Suffering From Schizophrenia-like Disorders
The study use a new ecological questionnaire called ESSME developed by a care team in order to evaluate ecological environment of patients with schizophrenia-like disorders.
- Trial name
- IEvaEcoSchi (NCT05349513)
- Testing
- ESSME questionnaire
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier Henri Laborit
Schizophrenia
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission.
- Trial name
- NCT06021197
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder, Healthy Adult
- Trial name
- CNTRACS 2 (NCT07875790)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia Disorders
Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia
Schizophrenia, affecting 1% of the population, is a persistent disorder characterized by varied symptoms. Antipsychotic medications effectively address positive symptoms (delusions, hallucinations) and relapse but have limited…
- Trial name
- ARCoS-2 (NCT07055204)
- Testing
- "Diapason & Metronome" musical learning
- Where
- 6 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Toulouse
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
Schizophrenia
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia.
- Trial name
- NCT04917302
- Testing
- NMDAE plus AIFA
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Schizophrenia
Temporal Interference Stimulation (TI) for Schizophrenia (SCZ)
This study will evaluate whether temporal interference (TI) stimulation, added to usual clinical treatment, improves symptoms of schizophrenia and is safe and tolerable.
- Trial name
- TI-SCZ-Insular (NCT07887997)
- Testing
- Active transcranial temporal interference stimulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Anhui Medical University
Completed, with results posted
All 744First Episode Psychosis
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
- Trial name
- NCT04046497
- Testing
- Smartphone App, Usual Care
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Northwell Health
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of…
- Trial name
- NCT04959032
- Testing
- Lumateperone 42 mg
- Where
- 43 sites in United States, Bulgaria and 2 more
- Volunteers
- 592 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Psychosis
Enhancing Mental Health Outcomes for Patients With Psychosis in Malawi Through Community-based Rehabilitation
The overall aim of the proposed study is to determine the feasibility, acceptability, fidelity, and preliminary effectiveness of the adapted nurse-led, community-based rehabilitation treatment model for community-dwelling…
- Trial name
- ENHANCE (NCT06080477)
- Testing
- Enhanced Usual Care, Adapted ENHANCE Intervention
- Where
- Malawi
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill